HEN methyltransferase 1Genealiases: C1orf59 · HEN1
Q-omics provides the consensus-scored HENMT1 profile across patient tissues and cancer cell-line models. HENMT1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, HENMT1 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, HENMT1 RNA expression shows 17,775 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, HNSC, and TGCT as cancer lineages where HENMT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HENMT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HENMT1 survival associations across molecular data types. HENMT1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HENMT1 RNA expression–survival associations across cancer types. High HENMT1 expression shows unfavorable associations in UCEC and MESO, but favorable associations in READ, HNSC, CESC and SCLC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for HENMT1 RNA expression.
This table summarizes HENMT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for HENMT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HENMT1 shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, BLCA, STAD and COAD. The HNSC box plot shows higher HENMT1 RNA expression in tumor versus normal tissue (log2 FC = +1.418, t-test p < 0.001).
This table shows molecular features associated with HENMT1 in patient tissues and cancer cell lines. In patient samples, HENMT1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, HENMT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
